RecruitingPhase 3NCT07804186
Oncology
Uveal Melanoma
Also known as ocular melanoma, choroidal melanoma, ciliary body melanoma, GNAQ/GNA11 mutation
Uveal melanoma is the most common primary intraocular malignancy in adults, arising from melanocytes of the uveal tract (choroid, ciliary body, or iris) and driven by activating somatic mutations in GNAQ or GNA11 in approximately 80% of cas
ORPHA:895 ↗Gene GNAQGene GNA11Gene BAP1Prevalence 5–6 in 1,000,000Onset Adult (median age 60s)Sporadic; BAP1 tumour predisposition syndrome in familial cases
40
studies recruiting now
as of 7 Sept 2026
296
studies registered in total
as of 7 Sept 2026
4
countries with a recruiting site
as of 7 Sept 2026
4 Sept 2026
most recent study posted
among recruiting studies
Recruiting trials
RecruitingPhase 1 / Phase 2NCT07636785
A Phase 1 and 2 Study of VMD-102 in Hepatocellular Carcinoma and Other Solid Tumors
RecruitingPhase 1NCT04855435
Safety and Preliminary Efficacy of MBS8(1V270) in Cancer Patients With Advanced Solid Tumours
RecruitingPhase 1 / Phase 2NCT06626516
Tebentafusp-tebn With LDT in Metastatic UM
RecruitingPhase 1NCT05607095
A Study of LN-144 or LN-145 in People With Advanced Uveal Melanoma, Undifferentiated Pleomorphic Sarcoma, Dedifferentiated Liposarcoma, or Angiosarcoma
Showing the 5 most recently updated recruiting studies, as recorded 7 Sept 2026. Live status on each study page.
See all 40 recruiting studiesWhere recruiting studies are running
Countries with at least one recruiting site among the studies above, 7 Sept 2026. Tap a country to search trials there.
Keep watching
Get an email when a new Uveal Melanoma study opens.
One email a day at most. Unsubscribe with one click.
Used only for these alerts. Privacy.
Support
Patient organisations
Registry: CURE OM Registry · Join ↗. Registries connect patients to researchers and often hear about trials first.
About Uveal Melanoma
Uveal melanoma is the most common primary intraocular malignancy in adults, arising from melanocytes of the uveal tract (choroid, ciliary body, or iris) and driven by activating somatic mutations in GNAQ or GNA11 in approximately 80% of cases, resulting in constitutive MAPK and YAP pathway signalling. Unlike cutaneous melanoma, uveal melanoma is largely unresponsive to anti-PD-1 checkpoint inhibitors used in isolation and lacks high tumour mutational burden or UV-signature mutations. Approximately 50% of patients develop metastatic disease, almost exclusively to the liver, with a median survival of 6–12 months from metastatic diagnosis; tebentafusp (a bispecific gp100-CD3 fusion protein) is the only therapy demonstrating improved overall survival in HLA-A*02:01-positive patients.
Common clinical features
Visual disturbance: blurred vision, photopsia (flashing lights), or visual field loss from the primary tumourAsymptomatic finding on routine dilated fundoscopic examination in a significant proportion of casesIntraocular pressure elevation from tumour-related secondary glaucomaPain or redness from iris or ciliary body tumours with anterior segment involvementHepatomegaly, right upper quadrant pain, or jaundice from hepatic metastasesConstitutional symptoms (fatigue, weight loss) in advanced metastatic diseaseSkin or subcutaneous metastases and orbital recurrence in rare advanced cases
From Orphanet’s phenotype annotations (CC BY 4.0). Not a complete list.
Treatments being studied
34 in clinical development, from Open Targets (CC BY 4.0). Not medical advice.
Phase 3Melphalan (Alkeran)
Phase 3Melphalan Hydrochloride (Alkeran)
Phase 3Dacarbazine (Dacarbazine)
Phase 3Tebentafusp (Kimmtrak)
Phase 3Darovasertib
Phase 3Melatonin (Circadin)
Phase 3Fotemustine
Phase 3Selumetinib
+ 26 more in development
Before you apply
Things trial teams commonly ask about for Uveal Melanoma. Not eligibility rules; those are set by each study.
- HLA-A*02:01 genotyping is mandatory for tebentafusp eligibility (approximately 40–50% of Caucasian patients are positive) — request HLA typing early as processing time may delay trial screening.
- BAP1 mutation and monosomy 3 status, determined from enucleation specimen or biopsy, are critical prognostic and eligibility markers for adjuvant and metastatic trials — confirm availability of tumour molecular data.
- Liver metastasis pattern (number and size of lesions) and hepatic reserve (liver function tests, Child-Pugh score) are key eligibility criteria for liver-directed and systemic therapy trials; provide recent cross-sectional imaging and laboratory values.
Related conditions
Information, not medical advice. Trial listings are shown as recorded on ClinicalTrials.gov; whether any study is right for you is a decision for you and your clinicians, and eligibility is decided by each research team. Disease information from Orphanet (CC BY 4.0).